Cargando…
Intravitreal triamcinolone acetonide for rebound phenomenon after high-dose intravenous steroid treatment in Vogt-Koyanagi-Harada disease
The authors report two cases of rebound phenomenon treated with intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada (VKH) disease. Patients in the acute phase of VKH disease were treated with high-dose intravenous (IV) methylprednisolone (1 g/day) for 3 days. Serous retinal detachment decre...
Autores principales: | Byon, Ik Soo, Kim, Ji Hun, Lee, Ji Eun, Oum, Boo Sup |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218169/ https://www.ncbi.nlm.nih.gov/pubmed/22125406 http://dx.doi.org/10.2147/OPTH.S25477 |
Ejemplares similares
-
Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis
por: Park, Jong G., et al.
Publicado: (2020) -
Rebound inflammation after an intravitreal injection in Vogt–Koyanagi–Harada syndrome
por: Ranjan, Richa, et al.
Publicado: (2018) -
Role of intravitreal triamcinolone as an adjuvant in the management of Vogt-Koyanagi-Harada disease
por: Moreker, Mayur R, et al.
Publicado: (2007) -
Comment on: Rebound inflammation after an intravitreal injection in Vogt–Koyanagi–Harada syndrome
por: Jain, Manish
Publicado: (2018) -
Response to comment on: Rebound inflammation after an intravitreal injection in Vogt–Koyanagi–Harada syndrome
por: Ranjan, Richa, et al.
Publicado: (2018)